Beximco Pharmaceuticals and Mylan signs an agreement
- February 27, 2020
- views
Beximco Pharmaceuticals signed a treaty with the Netherlands-based pharmaceuticals company Mylan recently. Both the companies are considering it as a groundbreaking commercial agreement.
Beximco Pharmaceuticals will launch key monoclonal antibodies from Mylan’s portfolio. The company plans to start with Ogivri. Ogivri is a breast cancer drug. According to statistics, there are 50,000 HER2-positive breast cancer patients in Bangladesh at the moment.
Gradually the company will launch drugs to treat rheumatoid arthritis, crohn’s disease, ulcerative colitis.
The drugs manufactured by Mylan are approved by the European Medicines Agency and US Food and Drug Administration.
Mylan and Beximco Pharmaceuticals share a common commitment to provide high-quality medicines to market.
Beximco Pharmaceuticals Limited, a concern of Beximco Group, is one of the leading and fast-growing manufacturers of generic pharmaceutical products in Bangladesh. It meets the local demand and exports in about 50 countries. Mylan is a Netherlands based Pharmaceuticals Company with diverse portfolios of biosimilars. The company is present in over 80 countries across the globe.
